Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical
company developing next-generation viral immunotherapies to
transform outcomes for cancer patients, today announced the
appointment of Scott Canute, M.B.A. to its Board of Directors. Mr.
Canute has nearly 40 years of broad experience in the
biopharmaceutical industry, including leading global manufacturing
and operations strategy and execution for Genzyme Corporation and
Eli Lilly and Company.
“As we execute on our growth plans, including the buildout of
our in-house manufacturing capabilities, we are delighted to
welcome Scott Canute to our Board of Directors,” said Theodore
(Ted) Ashburn, M.D., Ph.D., President and CEO of Oncorus. “We look
forward to leveraging Scott’s breadth of experience and insights
from leading operations and manufacturing for world-class
biopharmaceutical organizations as we advance our pipeline of novel
viral immunotherapies for cancer patients.”
Oncorus is advancing a portfolio of intratumorally and
intravenously administered viral immunotherapies for multiple
indications with significant unmet needs based on its oncolytic
Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform.
Oncorus is currently conducting a Phase 1 clinical trial of its
lead product candidate, ONCR-177, an intratumorally administered
oHSV viral immunotherapy being developed for multiple solid tumor
indications.
“I am thrilled to join Oncorus’ Board and support Ted and the
Oncorus team as they continue to advance ONCR-177 through the
clinic and embark on an exciting period of growth and
infrastructure development to support their expanding pipeline,”
said Mr. Canute. “Viral immunotherapies are increasingly gaining
attention for their unique and clinically-validated approach
against cancer. Oncorus’ dual-platform approach positions the
company as a leader in this space. I’m excited to have the
opportunity to contribute to Oncorus’ continued progression and
patient-centric mission.”
Mr. Canute previously served as President of Global
Manufacturing and Corporate Operations at Genzyme from 2010 to
2011, where he was brought in specifically to lead a major
turnaround in manufacturing to ensure the ongoing supply of the
company’s life-saving products. Prior to joining Genzyme, Mr.
Canute spent 25 years at Lilly, where he held several operations
and manufacturing roles of increasing responsibility, including
ultimately serving as President, Global Manufacturing Operations
from 2004 to 2007. In this role, Mr. Canute directed all
manufacturing and supply chain activities for Lilly’s global
operations.
Mr. Canute currently serves as a director of Flexion
Therapeutics. He previously served as a member of the Board of
Directors of Immunomedics Inc., Akebia Therapeutics, Inc., Proteon
Therapeutics, Inc., AlloCure, Inc., Inspiration Biopharmaceuticals,
Inc., Oncobiologics, Inc., and the National Association of
Manufacturers and the Indiana Manufacturers Association.
Mr. Canute earned a B.S. in chemical engineering from the
University of Michigan and an M.B.A. from Harvard Business
School.
About Oncorus
At Oncorus, we are focused on driving innovation to deliver
next-generation viral immunotherapies to transform outcomes for
cancer patients. We are advancing a portfolio of intratumorally and
intravenously administered viral immunotherapies for multiple
indications with significant unmet needs based on our oncolytic
Herpes Simplex Virus (oHSV) Platform and Synthetic Virus Platform.
Designed to deliver next-generation viral immunotherapy impact, our
oHSV Platform improves upon key characteristics of this therapeutic
class to enhance potency without sacrificing safety, including
greater capacity to encode transgenes to drive systemic
immunostimulatory activity, retention of full replication
competency to enable high tumor-killing potency, and orthogonal
safety strategies to restrict viral activity in tumor cells. Our
lead oHSV program, ONCR-177, is designed to be directly
administered into a tumor, resulting in high local concentrations
of the therapeutic agent, as well as low systemic exposure to the
therapy, which we believe could potentially limit systemic
toxicities. Please visit us at www.oncorus.com to learn
more.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, implied and
express statements regarding: expectations with respect to Oncorus’
ability to advance its clinical and pre-clinical pipelines,
including statements regarding the clinical development of
ONCR-177, expectations regarding upcoming milestones for its other
potential product candidates, as well as the therapeutic potential
and clinical benefits of Oncorus’ product candidates; Oncorus’
expectations with respect to its continued growth, including its
ability to expand its infrastructure and organization and its
ability to scale-up its platforms and buildout its manufacturing
capabilities; the ability of the leadership team to execute
Oncorus’ strategy and support its future growth; and statements
regarding the accomplishments, experience and capabilities of
individual members of Oncorus’ leadership team and the ability of
such qualities to drive Oncorus’ success. The words "may," “might,”
"will," "could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," “expect,” "estimate," “seek,” "predict,"
“future,” "project," "potential," "continue," "target" and similar
words or expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Any forward-looking statements in this
press release are based on management's current expectations and
beliefs and are subject to a number of risks, uncertainties and
important factors that may cause actual events or results to differ
materially from those expressed or implied by any forward-looking
statements contained in this press release, including, without
limitation, risks associated with: the impact of COVID-19 on
Oncorus’ operations and the timing and anticipated results of its
ongoing and planned clinical trials; the development of its
manufacturing capabilities and progression of its product
candidates into the operational scale-up phase; the risk that the
results of a clinical trial may not be predictive of future results
in connection with future clinical trials; Oncorus’s ability to
successfully demonstrate the safety and efficacy of ONCR-177 and
obtain regulatory approval; and Oncorus’ ability to obtain,
maintain and protect its intellectual property. These and other
risks and uncertainties are described in greater detail in the
section entitled "Risk Factors" in Oncorus’ Quarterly Report on
Form 10-Q for the quarter ended September 30, 2020, which was
filed with the Securities and Exchange Commission
on November 12, 2020, as well as discussions of potential
risks, uncertainties, and other important factors in the other
filings that Oncorus makes with the Securities and
Exchange Commission from time to time. These documents are
available under the “SEC filings” page of the Investors section of
Oncorus’s website at http://investors.oncorus.com.
Any forward-looking statements represent Oncorus’ views only as
of the date of this press release and should not be relied upon as
representing its views as of any subsequent
date. Oncorus explicitly disclaims any obligation to
update any forward-looking statements, whether as a result of new
information, future events or otherwise. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Investor Contact: |
Media Contact: |
Alan
Lada |
Liz
Melone |
Solebury
Trout |
liz.melone@oncorus.com |
617-221-8006 |
|
alada@soleburytrout.com |
|
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From May 2024 to Jun 2024
Oncorus (NASDAQ:ONCR)
Historical Stock Chart
From Jun 2023 to Jun 2024